Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Cetuximab

Nature Reviews Drug Discovery volume 3, pages 549–550 (2004)Cite this article

Abstract

Cetuximab (Erbitux; ImClone Systems/Bristol-Myers Squibb) is a monoclonal antibody that binds to the epidermal growth factor receptor, which is important in the growth of many cancers. In February 2004, it was granted accelerated approval by the FDA for the treatment of metastatic colorectal cancer on the basis of tumour response rates in Phase II trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: EGFR and the mode of action of cetuximab.
Figure 2: Market for drugs to treat colorectal cancer in US $ million.

References

  1. Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4–S66 (2001).

    Article  Google Scholar 

  2. Baselga, J. The EGFR as a target for anticancer therapy — focus on cetuximab. Eur. J. Cancer 37, S16–S22 (2001).

    Article  CAS  Google Scholar 

  3. Dancey, J. & Sausville, E. A. Issues and progress with protein kinase inhibitors for the treatment of cancer. Nature Rev. Drug Discov. 2, 296–313 (2003).

    Article  CAS  Google Scholar 

  4. Salomon, D. S. et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183–232 (1995).

    Article  CAS  Google Scholar 

  5. Goldstein, N. I. et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer. Res. 1, 1311–1318 (1995).

    CAS  PubMed  Google Scholar 

  6. FDA labelling information [online] (cited 6 May 2004) <http://www.fda.gov/cder/foi/label/2004/125084lbl.pdf> (2004).

  7. Prewett, M. C. et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. 8, 994–1003 (2002).

    CAS  PubMed  Google Scholar 

  8. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127–137 (2001).

    Article  CAS  Google Scholar 

  9. Burtness, B. A. et al. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc. Am. Soc. Clin. Oncol. 21, 226a (2002).

    Google Scholar 

  10. Caponigro, F. et al. New cytotoxic and molecular-targeted therapies of head and neck tumors. Curr. Opin. Oncol. 16, 225–230 (2004).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

  2. Decision Resources International, 50–51 Russell Square, London, WC1B 4HQ, UK

    Joanne Graham & Mohamed Muhsin

Authors
  1. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joanne Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Muhsin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joanne Graham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirkpatrick, P., Graham, J. & Muhsin, M. Cetuximab. Nat Rev Drug Discov 3, 549–550 (2004). https://doi.org/10.1038/nrd1445

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1445

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing